ProShare Advisors
KRYS icon

ProShare Advisors’s Krystal Biotech KRYS Stock Holding History

ProShare Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Sell
4,760
-417
-8% -$125K ﹤0.01% 700
2026
Q1 		$1.34M Sell
5,177
-939
-15% -$250K ﹤0.01% 739
2025
Q4 		$1.51M Buy
6,116
+399
+7% +$84K ﹤0.01% 735
2025
Q3 		$1.01M Sell
5,717
-908
-14% -$136K ﹤0.01% 811
2025
Q2 		$911K Sell
6,625
-526
-7% -$77.3K ﹤0.01% 858
2025
Q1 		$1.29M Sell
7,151
-1,697
-19% -$285K ﹤0.01% 750
2024
Q4 		$1.39M Buy
8,848
+1,967
+29% +$349K ﹤0.01% 792
2024
Q3 		$1.25M Buy
6,881
+1,727
+34% +$333K ﹤0.01% 753
2024
Q2 		$946K Sell
5,154
-711
-12% -$119K ﹤0.01% 761
2024
Q1 		$1.04M Buy
5,865
+486
+9% +$67.5K ﹤0.01% 777
2023
Q4 		$667K Buy
5,379
+740
+16% +$82.1K ﹤0.01% 884
2023
Q3 		$538K Buy
4,639
+158
+4% +$19.3K ﹤0.01% 889
2023
Q2 		$526K Buy
4,481
+185
+4% +$18.9K ﹤0.01% 924
2023
Q1 		$344K Sell
4,296
-577
-12% -$45.3K ﹤0.01% 1126
2022
Q4 		$386K Buy
4,873
+362
+8% +$26.9K ﹤0.01% 1092
2022
Q3 		$315K Buy
4,511
+161
+4% +$11.6K ﹤0.01% 1124
2022
Q2 		$285K Sell
4,350
-2,028
-32% -$126K ﹤0.01% 1240
2022
Q1 		$424K Sell
6,378
-668
-9% -$41.7K ﹤0.01% 1392
2021
Q4 		$493K Buy
7,046
+5
+0.1% +$291 ﹤0.01% 1453
2021
Q3 		$368K Sell
7,041
-1,600
-19% -$94.7K ﹤0.01% 1392
2021
Q2 		$588K Buy
8,641
+1,581
+22% +$110K ﹤0.01% 1418
2021
Q1 		$544K Buy
7,060
+1,022
+17% +$74.3K ﹤0.01% 1383
2020
Q4 		$362K Buy
+6,038
New +$302K ﹤0.01% 1485

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ProShare Advisors's KRYS Position: Q2 2026 in Review

ProShare Advisors reduced its Krystal Biotech (KRYS) stake by 8.1% in Q2 2026, selling an estimated $125K and leaving 4,760 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #700.

ProShare Advisors first reported a position in KRYS in Q4 2020 and has held it in 23 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • ProShare Advisors held 4,760 shares of Krystal Biotech worth $1.77M as of Q2 2026.
  • ProShare Advisors sold 417 Krystal Biotech shares in Q2 2026, an estimated $125K.
  • Krystal Biotech made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #700 holding.
  • ProShare Advisors first reported a position in Krystal Biotech in Q4 2020 and has held it in 23 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.